As discussed last month, new category III codes that could impact your interventional radiology coding services are now effective as of January 1, 2022. With these codes now active, interventional radiology providers and stakeholders should be aware of the scope of changes in place for the new year. New code 0644T mentioned in last month’s insight, has a significant amount of detail for correct coding and comprehension. By knowing the rationale, staff and coders can prepare for a successful year while safeguarding compliance.
So, what do the breast biopsy codes include? Breast biopsy codes include the following components:
Understand that guidance, localization device placement, and/or imaging of the removed specimen should not be separately coded when associated with a percutaneous biopsy.
It no longer matters whether the biopsy is performed using a rotating or vacuum-assisted device; instead, the code choice depends on the type of guidance. These codes may be used even when a localization device is not placed, or a surgical specimen is not x-rayed because the code description indicates “if performed.”
Frequently, a clip is placed at the biopsy site after a percutaneous biopsy. These clips can be seen under radiographic imaging and are placed in case other intervention is later required. The clip indicates the location of the biopsy site. Clip placement is included in the percutaneous breast biopsy codes when performed by the same physician at the same session.
There are several types of guidance including:
For each type of guidance, there is a code for first lesion and another for each additional lesion. The “each additional lesion” code would be assigned for a second lesion biopsied using the same type of guidance, whether in the same or opposite breast as the first lesion.
Understand that it is not appropriate to report an initial lesion code with modifier 50 for biopsy of bilateral lesions using the same type of guidance. Coding would be the same if a single lesion is biopsied in each breast or if two lesions in one breast are separately biopsied using the same type of guidance. If bilateral lesions or two lesions in one breast are separately biopsied using different types of guidance, assign the appropriate “first lesion” code for each.
For example, if a lesion in the right breast is biopsied using ultrasound guidance, and a separate lesion in the same breast must be biopsied under MRI guidance, you would submit codes 19083 and 19085. However, if separate lesions in the left and right breast are both biopsied using ultrasound guidance, codes 19083 and 19084 would be reported.
| 19081 | Biopsy, breast, with placement of breast localization device(s) (e.g., clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including stereotactic guidance |
| +19082 | Biopsy, breast, with placement of breast localization device(s) (e.g., clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; each additional lesion, including stereotactic guidance (List separately in addition to code for primary procedure) |
| 19083 | Biopsy, breast, with placement of breast localization device(s) (e.g., clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including ultrasound guidance |
| +19084 | Biopsy, breast, with placement of breast localization device(s) (e.g., clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; each additional lesion, including ultrasound guidance (List separately in addition to code for primary procedure) |
| 19085 | Biopsy, breast, with placement of breast localization device(s) (e.g., clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including magnetic resonance guidance |
| +19086 | Biopsy, breast, with placement of breast localization device(s) (e.g., clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; each additional lesion, including magnetic resonance guidance (List separately in addition to code for primary procedure) |
There is no longer a code for mammographic guidance for needle placement. If a percutaneous breast biopsy is performed under mammographic guidance, the unlisted surgical code 19499 should be assigned. Code 19499 also should be reported if CT guidance is used for a percutaneous breast biopsy.
| 19499 | Unlisted procedure, breast
Note that if a percutaneous breast biopsy is performed without imaging guidance, code 19100 would be appropriate. |
| 19100 | Biopsy of breast; percutaneous, needle core, not using imaging guidance (separate procedure) |
So how is aspiration biopsy coded? Aspiration biopsy of the breast is coded using the appropriate generic FNA code (10021, 10004-10012). Note that coders sometimes have trouble deciding between an FNA and breast cyst aspiration (19000-19001). The FNA code would be assigned when the intent of the procedure was to obtain a sample of cells or fluid for diagnostic evaluation, even if the lesion was a cyst. Code 19000 is assigned if the intent was to drain a cyst, even if the aspirated material is sent to the lab for cytologic evaluation.
Explore more topics, crack through the complexity of interventional radiology, and master more coding through expert-infused tips by using our Essentials of Interventional Radiology Coding resource. Create success for 2022 and beyond.
Information source for breast biopsy statistic:
https://www.cbsnews.com/news/breast-biopsies-often-get-it-wrong/
Vaccines have been in the news recently, making it a good time to take a look at our coding for vaccinations. In our Alphabetic Index,
This week I’m continuing my focus on defining documentation, this time with a real-world example that many of you may have encountered. As noted last
Please log in to your account to comment on this article.
Only ICD10monitor delivers what you need: updates on must-know changes associated with the FY26 IPPS, including new ICD-10-CM/PCS codes, CCs/MCCs, and MS-DRGs, plus insights, analysis and answers to your questions from two of the country’s most respected subject matter experts.
This third session in our 2026 IPPS Masterclass will feature a review of FY26 changes to the MS-DRG methodology and new technology add-on payments (NTAPs), presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.
This second session in our 2026 IPPS Masterclass will feature a review the FY26 changes to ICD-10-PCS codes. This information will be presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.
This first session in our 2026 IPPS Masterclass will feature an in-depth explanation of FY26 changes to ICD-10-CM codes and guidelines, CCs/MCCs, and revisions to the MCE, presented by presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.
RACmonitor is proud to welcome back Dr. Ronald Hirsch, one of his most requested webcasts. In this highly anticipated session, Dr. Hirsch will break down the complex Two Midnight Rule Medicare regulations, translating them into clear, actionable guidance. He’ll walk you through the basics of the rule, offer expert interpretation, and apply the rule to real-world clinical scenarios—so you leave with greater clarity, confidence, and the tools to ensure compliance.
Bring your questions and join the conversation during this open forum series, live every Wednesday at 10 a.m. EST from June 11–July 30. Hosted by Chuck Buck, these fast-paced 30-minute sessions connect you directly with top healthcare experts tackling today’s most urgent compliance and policy issues.
Fraud convictions don’t just punish a few bad claims; they can wipe out years of reimbursements. Don’t wait for an audit to learn the rules. Join Frank Cohen, MPA, for a live Q&A on spotting red flags, avoiding liability, and protecting your practice. Register now and bring your questions!
Substance abuse is everywhere. It’s a complicated diagnosis with wide-ranging implications well beyond acute care. The face of addiction continues to change so it’s important to remember not just the addict but the spectrum of extended victims and the other social determinants and legal ramifications. Join John K. Hall, MD, JD, MBA, FCLM, FRCPC, for a critical Q&A on navigating substance abuse in 2025. Register today and be a part of the conversation!
Copyright © 2025 ICD10monitor. Powered by MedLearn Media.
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
